Table 1.

Clinical characteristics of the study population and controls

	Controls	MHD patients
n	12	19
Male	6 (50)	12 (63)
Age, years	42 (39–50)	56 (45–57)*
Disease history
Myocardial infarction	0 (0)	0 (0)
Hypertension	0 (0)	17 (89)*
Diabetes mellitus	0 (0)	2 (11)
Hypercholesterolemia	0 (0)	2 (11)
NAFLD	0 (0)	1 (5)
Systolic blood pressure, mm Hg	123.1±15.6	143.3±28.1*
Diastolic blood pressure, mm Hg	81.0±12.1	70.8±22.6*
Laboratory values
Hemoglobin, g/L	−	100.4±15.5
Parathyroid hormone, pg/mL	−	222.3±196.1
Calcium, mmol/L	−	2.3±0.2
Phosphorus, mmol/L	−	1.6±0.4
Medication
Use of CCB	−	11 (58)
Use of ARB	−	2 (11)
Use of ACEI	−	5 (26)
Use of β-receptor blocker	−	10 (53)
Use of aspirin	−	1 (5)
Statins	−	6 (32)
Weekly dose of epoetin, IU	−	3,000 (3,000–6,000)

Values expressed as n (%), mean ± SE, or median (IQR). * p < 0.05, compared with healthy controls. Comparisons between 2 groups were performed using the Mann-Whiteny U test. MHD, maintenance hemodialysis; NAFLD, non-alcoholic fatty liver disease; CCB, calcium-channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker.